Compare BELFB & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BELFB | VIR |
|---|---|---|
| Founded | 1949 | 2016 |
| Country | United States | United States |
| Employees | 5370 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 773.5M |
| IPO Year | N/A | 2019 |
| Metric | BELFB | VIR |
|---|---|---|
| Price | $166.83 | $6.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | ★ $153.75 | $25.73 |
| AVG Volume (30 Days) | 154.5K | ★ 1.8M |
| Earning Date | 10-29-2025 | 11-05-2025 |
| Dividend Yield | ★ 0.16% | N/A |
| EPS Growth | ★ 19.52 | N/A |
| EPS | ★ 5.17 | N/A |
| Revenue | ★ $649,376,000.00 | $16,860,000.00 |
| Revenue This Year | $28.52 | N/A |
| Revenue Next Year | $6.49 | $48.05 |
| P/E Ratio | $33.23 | ★ N/A |
| Revenue Growth | ★ 23.70 | N/A |
| 52 Week Low | $58.00 | $4.16 |
| 52 Week High | $178.67 | $14.45 |
| Indicator | BELFB | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 56.19 | 48.14 |
| Support Level | $168.49 | $6.49 |
| Resistance Level | $178.67 | $6.97 |
| Average True Range (ATR) | 7.58 | 0.47 |
| MACD | 0.74 | -0.02 |
| Stochastic Oscillator | 58.13 | 41.30 |
Bel Fuse Inc designs and manufactures electronic components that protect and connect electronic circuits. Its product portfolio is divided into three categories: magnetic solutions, power solutions & protection, and connectivity solutions. These products are used for the computer, networking, telecommunications, transportation and defense/aerospace, automotive, medical, and consumer electronics industries. Its geographical segments are the United States, Macao, United Kingdom, Slovakia, Germany, Switzerland, and All other foreign countries. Majority of the revenue is derived from United States.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.